When we think about difficult-to-manufacture medicines, attention often goes to newer and more technically sophisticated therapeutic classes. Yet manufacturing complexity is hardly limited to novel modalities. Many established drug products rely on equally specialized science to turn an API into a dosage form that is practical for patients and reproducible at commercial scale. Even products as familiar as tablets and liquid medicines can require manufacturers to overcome challenges related to solubility, stability, drug release, dose uniformity, or patient acceptability.
These challenges are often largely invisible once a medicine reaches the patient. That is precisely the goal: the technical complexity involved in making a product should not translate into complexity for the person taking it. Behind that simplicity, however, are carefully selected formulation strategies, well-controlled manufacturing processes, and teams with the expertise to anticipate how decisions made during development will affect production later. Here are five areas where that expertise becomes particularly important.
1. API properties shape the path forward
The familiarity of oral solid dosage (OSD) forms can obscure how much their development depends on the characteristics of the API itself. Low aqueous solubility, for example, can create bioavailability challenges, while particle size, morphology, and other material properties can influence powder handling and downstream processing. Thermal or moisture sensitivity may further limit which formulation and manufacturing approaches are practical. Addressing these issues requires developers to build a detailed understanding of the molecule and use that knowledge to guide formulation strategy. Depending on the challenge, approaches may include particle-size reduction or amorphous solid dispersion technologies such as hot-melt extrusion or spray drying. Selecting among these options requires consideration of both immediate formulation goals and future manufacturing needs. An experienced CDMO can help sponsors assess those tradeoffs early, drawing on expertise across different molecules, technologies, and manufacturing environments to identify an approach that can ultimately be translated to larger-scale production.
2. Modified release depends on tight process control
The convenience of taking a medicine once rather than several times a day can be enabled by surprisingly sophisticated formulation science. Modified-release products must deliver an API according to a defined profile, which may require polymer-based matrices, multiparticulate formulations, functional coatings, extrusion-spheronization, or other specialized technologies. Their performance can be sensitive to variations in raw materials and processing conditions, making a strong understanding of critical material attributes and process parameters essential. Manufacturing considerations therefore need to enter the conversation early. It is not enough to demonstrate that a formulation produces the desired release profile at laboratory scale; developers must also consider whether that performance can be maintained as batch sizes increase and the process moves into different equipment and manufacturing environments. Bringing development and manufacturing expertise together early can help sponsors select approaches that meet product requirements without creating avoidable scale-up or technology transfer challenges later.
3. Designing around the patient can add manufacturing complexity
Patient needs can also shape the technical requirements of a product. Conventional tablets may be difficult for pediatric or older populations to swallow, for example, creating demand for liquids, suspensions, smaller tablets, powders, or other alternatives. Improving usability in this way introduces a different set of development considerations. Suspensions need appropriate physical properties to support consistent dosing, while liquid products bring their own requirements around stability, mixing, filling, packaging, and, in some cases, taste masking. Additional product characteristics can further increase manufacturing demands. Highly potent APIs require appropriate containment, controlled substances require rigorous material controls and careful production planning, and solvent-based processes require suitable infrastructure and operating expertise. A CDMO with these capabilities already integrated into its network can help sponsors address formulation, handling, and manufacturing requirements as interconnected parts of the same development strategy.
4. Processes must be designed to withstand scale-up
A formulation that works well during development still has to make the transition into routine manufacturing. As production moves to larger equipment and batch sizes, factors such as powder behavior, mixing, residence time, and heat or mass transfer can change in ways that affect process performance. Successful scale-up therefore depends on understanding which variables matter most and establishing controls capable of maintaining product quality under commercial conditions. Technology transfer is a critical part of that process because it converts development knowledge into manufacturing practice. Continuity between development, scale-up, transfer, and commercial production can reduce the risk of losing valuable process understanding at each transition. When the same CDMO supports multiple stages of the product lifecycle, teams can consider commercial requirements earlier and carry lessons from development forward as the process matures.
5. Sustained commercial performance requires technical stewardship
Once commercial production begins, the need for scientific and technical expertise does not disappear. Reliable supply requires ongoing coordination among process development, analytical sciences, manufacturing, quality, supply chain, and other functions, particularly for products that rely on specialized technologies. Manufacturing science and technology (MSAT) teams can provide an important bridge between these disciplines by maintaining process knowledge and applying it when deviations arise, variability needs to be understood, or processes require optimization. This is also why manufacturing capabilities cannot be evaluated solely by looking at equipment or available capacity. Platforms for modified release, bioavailability enhancement, potent compound handling, or specialized dosage forms are most valuable when backed by teams that understand how to apply them and maintain robust processes over the long term. For sponsors, that combination of infrastructure and expertise can make a CDMO an ongoing technical partner rather than simply a source of production capacity.
The apparent simplicity of an everyday medicine is often the result of considerable complexity being managed successfully behind the scenes. From selecting a formulation strategy to establishing a scalable process and maintaining it throughout commercial production, each stage requires decisions that can influence the next. Combining specialized capabilities with experienced development, manufacturing, and MSAT teams helps ensure those decisions are made with the full product lifecycle in mind. Ultimately, making a medicine straightforward and reliable for patients starts with having the expertise to navigate everything that makes it difficult to manufacture.